EVOKE PHARMA INC : Other Events (form 8-K)

Published: 2021-10-20 08:32:06 ET EVOK

Item 8.01. Other Events.

On October 20, 2021, Evoke Pharma, Inc. ("Evoke" or the "Company") and EVERSANA™, the Company's commercialization partner, announced positive findings from a recent market research study conducted for GIMOTI® (metoclopramide) nasal spray. The study aimed to gather additional market insights on the perception of GIMOTI in the Gastroenterology and other health care provider communities during September 2021 and follows prior market research studies conducted since product launch. The Company will share the findings in discussions at the upcoming American College of Gastroenterology (ACG) Conference, an important gastroenterology conference focused on clinical practice, being held October 22 - 27 in Las Vegas, NV.

The Company cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding: potential future prescribing trends for GIMOTI based on this survey of GIs and PCPs or the Company's marketing efforts; and the Company's commercialization plans, including its plans to increase awareness and access to GIMOTI. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company's business, including, without limitation: the Company's and EVERSANA's ability to successfully drive market demand for GIMOTI; the results of the ATU survey may not predict prescribing trends by doctors or acceptance by patients, and are not intended to reflect or imply actual prescriptions or sales to date; the Company's ability to obtain additional financing as needed to support its operations; the COVID-19 pandemic may continue to disrupt the Company's and EVERSANA's business operations impairing the ability to commercialize GIMOTI and the Company's ability to generate any product revenue; the Company's dependence on third parties for the manufacture of GIMOTI; the Company is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; and other risks and uncertainties detailed in the Company's prior reports and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

--------------------------------------------------------------------------------